Beyond The Numbers: 6 Analysts Discuss GE HealthCare Techs Stock

Loading...
Loading...

Analysts' ratings for GE HealthCare Techs GEHC over the last quarter vary from bullish to bearish, as provided by 6 analysts.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 0 2 0 0
Last 30D 1 0 0 0 0
1M Ago 1 0 0 0 0
2M Ago 2 0 2 0 0
3M Ago 0 0 0 0 0

Analysts have set 12-month price targets for GE HealthCare Techs, revealing an average target of $97.17, a high estimate of $110.00, and a low estimate of $86.00. This current average has increased by 20.86% from the previous average price target of $80.40.

Understanding Analyst Ratings: A Comprehensive Breakdown

The analysis of recent analyst actions sheds light on the perception of GE HealthCare Techs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Joanne Wuensch Citigroup Raises Buy $103.00 $88.00
David Toung Argus Research Raises Buy $110.00 $80.00
Sezgi Oezener HSBC Announces Buy $100.00 -
Patrick Wood Morgan Stanley Raises Equal-Weight $86.00 $74.00
Graham Doyle UBS Raises Neutral $88.00 $66.00
Anthony Petrone Mizuho Raises Buy $96.00 $94.00

Key Insights:

Loading...
Loading...
  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to GE HealthCare Techs. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GE HealthCare Techs compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for GE HealthCare Techs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of GE HealthCare Techs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on GE HealthCare Techs analyst ratings.

Delving into GE HealthCare Techs's Background

GE HealthCare Technologies Inc is a globally medical technology, pharmaceutical diagnostics, and digital solutions innovator company. It has four operating segments; Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It earns a majority of its revenue from the Imaging segment.

Key Indicators: GE HealthCare Techs's Financial Health

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: GE HealthCare Techs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 5.43%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: GE HealthCare Techs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 7.74%, the company may face hurdles in effective cost management.

Return on Equity (ROE): GE HealthCare Techs's ROE excels beyond industry benchmarks, reaching 5.65%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.24%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.38, caution is advised due to increased financial risk.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...